1. Cardiac Tamponade During Tocilizumab Therapy in a Patient with Rheumatoid Arthritis and Anti-DNA Antibody Positivity
- Author
-
Yoshifumi Okano, Yuichi Moriyama, Yuka Yamazaki, Harumizu Sakurada, Daisuke Miyahara, and Hironobu Tanii
- Subjects
rheumatoid arthritis ,Male ,musculoskeletal diseases ,medicine.medical_specialty ,Anti-nuclear antibody ,Case Report ,030204 cardiovascular system & hematology ,Antibodies, Monoclonal, Humanized ,Chest pain ,Pericardial effusion ,Gastroenterology ,Arthritis, Rheumatoid ,tocilizumab ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Tocilizumab ,immune system diseases ,adverse effect ,Internal medicine ,Cardiac tamponade ,Internal Medicine ,Humans ,Lupus Erythematosus, Systemic ,Medicine ,skin and connective tissue diseases ,Aged ,Systemic lupus erythematosus ,Lupus erythematosus ,business.industry ,interleukin-6 ,drug-induced lupus ,General Medicine ,medicine.disease ,pericardial effusion ,Cardiac Tamponade ,chemistry ,Rheumatoid arthritis ,030211 gastroenterology & hepatology ,medicine.symptom ,business - Abstract
Drug-induced lupus (DIL) is a drug-mediated immune reaction with the same symptoms as that of lupus erythematosus. We herein report the first case of tocilizumab-induced lupus syndrome presenting with cardiac tamponade. A 65-year-old man presented with cough, exertional dyspnea, and chest pain after 2 months of tocilizumab therapy for rheumatoid arthritis. Echocardiography revealed marked pericardial effusion. Antinuclear antibodies and anti-double-stranded deoxyribonucleic acid antibodies were positive. The diagnosis of cardiac tamponade due to tocilizumab-induced lupus syndrome was made. He had no recurrence of pericardial effusion after tocilizumab discontinuation. Clinicians should be alert for lupus syndrome in patients receiving tocilizumab.
- Published
- 2021
- Full Text
- View/download PDF